Antiretroviral therapy-naïve people living with HIV tend to have more severe symptoms of COVID-19

Lignende værker

• Efficacy and Safety of Switching to Dolutegravir/Lamivudine in Virologically Suppressed HIV-1 Infected Adults with TDF-Related Renal or Bone Toxicity
  af: Zhenyan Wang, et al.
  Udgivet: (2026-05-01)
• Switching to Dolutegravir + Lamivudine in a Highly Treatment-Experienced Patient Living with Human Immunodeficiency Virus Infection
  af: Deniz GÖKENGİN, et al.
  Udgivet: (2022-12-01)
• Real-world experience of Dolutegravir/Lamivudine for rapid initiation of antiretroviral therapy among treatment-naïve HIV-1-infected adults in China: a multicenter retrospective study
  af: Aixin Li, et al.
  Udgivet: (2026-02-01)
• Real-World Effectiveness, Tolerability, and Safety of Dolutegravir/Lamivudine in Korea
  af: Ki Hyun Lee, et al.
  Udgivet: (2022-11-01)
• DOLAMA 200: Effectiveness and Safety of a Dual Therapy with Dolutegravir Plus Lamivudine in Treatment-Experienced HIV-1 Infected Real World Participants in Spain
  af: Sergio Sequera-Arquelladas, et al.
  Udgivet: (2024-02-01)